Placental Growth Factor in Patients with pregnancy complications in the third trimester of pregnancy
Authors:
A. Muravská 1; A. Germanová 2; M. Jáchymová 1; A. Kuběna 1; Z. Hájek 2; A. Pařízek 2; T. Zima 1; M. Kalousová 1
Authors place of work:
Ústav lékařské biochemie a laboratorní diagnostiky, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
1; Gynekologicko-porodnická klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
2
Published in the journal:
Klin. Biochem. Metab., 26, 2018, No. 3, p. 114-118
Summary
Objective:
The aim of the study was to investigate placental growth factor (PLGF) plasma levels in patients with pathological states in pregnancy.
Design:
Case-control study.
Settings:
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Kateřinská 32, 121 08 Prague, Czech Republic.
Material and Methods:
The studied group consisted of together 151 women in the third trimester of pregnancy (35 patients with threatening preterm labor, 32 patients with hypertensive disorder, 30 patients with intrauterine growth restriction (IUGR), 13 patients with pregnancy intrahepatic cholestasis (ICP) and 41 healthy pregnant controls). PLGF was measured by ELISA.
Results:
Patients with preeclampsia and IUGR had significantly decreased PLGF levels compared to controls, (90.6 (IQR 49.9 – 122.4) pg/ml; resp. 56.0 (IQR 39.6 – 143.1) pg/ml vs. 183.9 (IQR 114.0 – 302.2) pg/ml, p < 0.0001), whereas PLGF levels in patients with preterm labor and ICP did not differ from control group. After gestational age adjustment, all groups of patients significantly differ from control group. PLGF correlates negatively with both erythrocyte count and hemoglobin levels in patients with preterm labor (r = –0.46 p = 0.0058 resp. r = – 0.53, p = 0.0013) and with uric acid in patients with IUGR (r = – 0.4237, p = 0.0196).
Conclusion:
Results of the study contribute to better understanding of the pathological mechanisms in risk pregnancy.
Keywords:
intrahepatic cholestasis of pregnancy, intrauterine growth restriction, PLGF, preeclampsia, preterm labor.
Zdroje
1. McColl, B. K., Stacker, S. A., Achen, M. G. Molecular regulation of the VEGF family – inducers of angiogenesis and lymphangiogenesis. APMIS, 2004, 112, s. 463–80.
2. Makrydimas, G., Sotiriadis, A., Savvidou, M. D., Spencer, K., Nicolaides, K. H. Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy. Prenat. Diagn., 2008, 28, s. 175–9.
3. Ribatti, D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008, 11, s. 215–21.
4. Park, J. E., Chen, H. H., Winer, J., Houck, K. A., Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 1994, 269, s. 25646–54.
5. Eriksson, A., Cao, R., Pawliuk, R., et al. Placenta Growth Factor-1 antagonizes VEGF-induced angioge-nesis and tumor growth by the formation of functionally inactive PIGF-1/VEGF heterodimers. Cancer Cell., 2002, 1, s. 99–108.
6. Clark, D. E., Smith, S. K., Licence, D., Evans, A. L., Charnock-Jones, D. S. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J. Endocrinol., 1998, 159, s. 459–67.
7. Metoda – Lidský placentární růstový hormon (PlGF, marker preeklampsie). [online]. Ústav klinické biochemie a diagnostiky FN v Hradci Králové, 31. 5. 2017. [cit. 12. 6. 2018]. Dostupné z: http://ukbd.fnhk.eu/metoda-lidsky-placentarni-rustovy-hormon-plgf-marker-preeklampsie.html
8. Benton, S. J., McCowan, L. M., Heazell, A. E., et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta, 2016, 42, s. 1–8.
9. Tarasevičienė, V., Grybauskienė, R., Mačiulevičienė, R. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics. Medicina (Kaunas), 2016, 52, s. 349–53.
10. Kagan, K. O., Hoopmann, M., Abele, H., Alkier, R., Luthgens K. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound. Obstet. Gynecol., 2012, 40, s. 530–5.
11. Theilade, S., Lajer, S., Jorsal, M., Tarnow, L., Par-ving H. H., Rossing, P. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. Diabet. Med., 2012, 29, s. 337–44.
12. Muravská, A., Germanová, A., Jáchymová, M., et al. Association of Pregnancy-associated plasma protein A polymorphism with preeclampsia – A pilot study. Clin. Biochem., 2011, 44, s. 1380–4.
13. Erez, O., Romero, R., Espinoza, J., et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent deve-lopment of preeclampsia and small-for-gestational age. J. Matern. Fetal. Neonatal. Med., 2008, 21, s. 279–87.
14. Hanita, O., Alia, N. N., Zaleha, A. M., Nor Azlin, M. I. Serum soluble FMS-like tyrosine kinase 1 and placental growth factor concetration as predictors of preeclampsia in high risk pregnant women. Malays. J. Pathol., 2014, 36, s. 19-26.
15. Gurnadi, J. I., Mose, J., Handono, B., et al. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. BMC Res. Notes., 2015, 4, s. 534.
16. Molvarec, A., Szarka, A., Walentin, S., Szucs, E., Nagy, B., Rigó, J. Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens. Res., 2010, 33, s. 892–8.
17. Wallner, W., Sengenberger, R., Strick, R., et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci. (Lond.), 2007, 112, s. 51–7.
18. Chaiworapongsa, T., Romero, R., Tarca, A., et al. A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J. Matern. Fetal. Neonatal. Med., 2009, 22, s. 1122–39.
19. Patrelli, T. S., Gizzo, S., Plebani, M., et al. The trend of VEGF-A and PlGF in pregnant patients: a perspective case-control study on 214 women. Clin. Exp. Obstet. Gynecol., 2012, 39, s. 57–64.
20. Ovadia, C., Williamson, C. Intrahepatic cholestasis of pregnancy: Recent advances. Clin. Dermatol., 2016, 34, s. 327-34.
21. Patel, S., Pinheiro, M., Felix, J. C., Opper, N., Ouzounian, J. G., Lee, R. H. A case-control review of placentas from patients with intrahepatic cholestasis of pregnancy. Fetal. Pediatr. Pathol., 2014, 33, s. 210–5.
22. Sundaram, N., Tailor, A., Mendelsohn, L., et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood, 2010, 116, s. 109–12.
23. Karowicz-Bilinska, A., Kedziora-Kornatowska, K., Bartosz, G. Indices of oxidative stress in pregnancy with fetalgrowth restriction. Free Radic. Res., 2007, 41, s. 870–3.
24. Takagi, Y., Nikaido, T., Toki, T., et al. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch., 2004, 444, s. 49–55.
25. Glantzounis, G. K., Tsimoyiannis, E. C., Kappas, A. M., Galaris, D. A. Uric acid and oxidative stress. Curr. Pharm. Des., 2005, 11, s. 4145–51.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2018 Číslo 3
Najčítanejšie v tomto čísle
- Advantages of anti-myeloperoxidase and anti-proteinase-3 antibodies detection by chemiluminescence method in patients with ANCA-associated vasculitis
- Placental Growth Factor in Patients with pregnancy complications in the third trimester of pregnancy
- Deepening oxidative stress in pancreatic cancer due to malnutrition